Sanofi (SNY,SAN.PA) reported that the LEAP2MONO phase 3 study demonstrated that venglustat met the primary and three out of four key secondary endpoints in adults and pediatric patients with neurological manifestations of type 3 Gaucher disease. Venglustat demonstrated superiority versus enzyme replacement therapy in addressing neurological symptoms. Also, Venglustat was well tolerated overall with no new safety signals. Sanofi said it will pursue global regulatory filings for venglustat in GD3.
Houman Ashrafian, Executive Vice President and Head of Research and Development at Sanofi, said: "What excites us most is the potential to address critical unmet medical needs. A daily pill could make a serious difference for Gaucher patients facing neurological challenges."
Sanofi shares are trading at 79.20 euros, up 2.75%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.